Described herein are interleukin-18 receptor binding moieties and uses thereof. An interleukin-18 receptor binding moiety can be an interleukin-18 receptor agonist or antagonist. An interleukin-18 receptor agonist can be an interleukin-18 receptor alpha binding moiety, an interleukin-18 receptor beta binding moiety, or can include interleukin-18 receptor alpha binding moiety and an interleukin-18 receptor beta binding moiety. An interleukin-18 receptor antagonist can be an interleukin-18 receptor alpha binding moiety, an interleukin-18 receptor beta binding moiety, or can include interleukin-18 receptor alpha binding moiety and an interleukin-18 receptor beta binding moiety. Interleukin-18 receptor agonists and interleukin-18 receptor antagonists can be formulated in a pharmaceutical formulation. Interleukin-18 receptor agonists and interleukin-18 receptor antagonists are useful for treating diseases and disorders in a subject in need thereof
The use of IL-7Rαγc agonist peptides in cell manufacturing is disclosed. The IL-7Rαγc agonist peptides can facilitate the selective growth of immune cell populations. Culture media comprising the IL-7Rαγc agonist peptides, methods of expanding a target immune cell population, and methods of manufacturing a target immune cell population are disclosed. The enriched immune cell populations can be used in immunotherapy.
The use of IL-2Rβγc agonist peptides in cell manufacturing is disclosed. The IL-2Rβγc agonist peptides can facilitate the selective growth of immune cell populations. Culture media comprising the IL-2Rβγc agonist peptides, methods of expanding a target immune cell population, and methods of manufacturing a target immune cell population are disclosed. The enriched immune cell populations can be used in immunotherapy.
The use of IL-7Rαγc agonist peptides in cell manufacturing is disclosed. The IL-7Rαγc agonist peptides can facilitate the selective growth of immune cell populations. Culture media comprising the IL-7Rαγc agonist peptides, methods of expanding a target immune cell population, and methods of manufacturing a target immune cell population are disclosed. The enriched immune cell populations can be used in immunotherapy.
The use of IL-2Rβγc agonist peptides in cell manufacturing is disclosed. The IL-2Rβγc agonist peptides can facilitate the selective grow th of immune cell populations. Culture media comprising the IL-2Rβγc agonist peptides, methods of expanding a target immune cell population, and methods of manufacturing a target immune cell population are disclosed. The enriched immune cell populations can be used in immunotherapy.
Described herein are interleukin-18 receptor binding moieties and uses thereof. An interleukin-18 receptor binding moiety can be an interleukin-18 receptor agonist or antagonist. An interleukin-18 receptor agonist can be an interleukin-18 receptor alpha binding moiety, an interleukin-18 receptor beta binding moiety, or can include interleukin-18 receptor alpha binding moiety and an interleukin-18 receptor beta binding moiety. An interleukin-18 receptor antagonist can be an interleukin-18 receptor alpha binding moiety, an interleukin-18 receptor beta binding moiety, or can include interleukin-18 receptor alpha binding moiety and an interleukin-18 receptor beta binding moiety. Interleukin-18 receptor agonists and interleukin-18 receptor antagonists can be formulated in a pharmaceutical formulation. Interleukin-18 receptor agonists and interleukin-18 receptor antagonists are useful for treating diseases and disorders in a subject in need thereof.
IL-7Rαγc binding compounds and pharmaceutical compositions comprising the IL-7Rαγc binding compounds are disclosed. IL-7Rαγc bonding compounds can act as IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.
IL-2Rβγc binding compounds, and pharmaceutical compositions comprising the IL-2Rβγc binding compounds are disclosed. IL-2Rβγc binding compounds can act as IL-2R agonists and are useful in treating cancer, autoimmune diseases and inflammatory diseases.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
IL-2Rβ ligands and IL-2Rγc ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2Rβ ligands and/or the IL-2Rγc ligands can be IL-2 receptor agonists.
IL-2Rβ ligands and IL-2Rγc ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2Rβ ligands and/or the IL-2Rγc ligands can be IL-2 receptor agonists.
IL-2R??c binding compounds, and pharmaceutical compositions comprising the IL-2R??c binding compounds are disclosed. IL-2R??c binding compounds can act as IL-2R agonists and are useful in treating cancer, an autoimmune disease, and an inflammatory disease.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
IL-2Rβγc binding compounds, and pharmaceutical compositions comprising the IL-2Rβγc binding compounds are disclosed. IL-2Rβγc binding compounds can act as IL-2R agonists and are useful in treating cancer, an autoimmune disease, and an inflammatory disease.
IL-2Rβγc binding compounds, and pharmaceutical compositions comprising the IL-2Rβγc binding compounds are disclosed. IL-2Rβγc binding compounds can act as IL-2R agonists and are useful in treating cancer, an autoimmune disease, and an inflammatory disease.
Dual receptor binding compounds comprising IL-2Rβ, IL-7Rα, and Rγc ligands, and pharmaceutical compositions comprising the dual receptor binding compounds are disclosed. The dual receptor binding compounds can act as IL-2R and IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
IL-7Rα ligands and compounds comprising IL-7Rα ligands are disclosed. The IL-7Rα binding compounds include fusion proteins comprising the IL-7Rα ligands and can act as IL-7R agonists.
Peptidyl IL-2Rα ligands and compounds comprising the IL-2Rα ligands are disclosed. The IL-2Rα ligands and compounds such as synthetic monomers, homodimers, or heteromers and recombinant fusion proteins comprising the IL-2Rα ligands can be used as targeting or imaging agents, as diagnostics or to treat cancers and autoimmune diseases.
IL-7Rα ligands and compounds comprising IL-7Rα ligands are disclosed. The IL-7Rα binding compounds include fusion proteins comprising the IL-7Rα ligands and can act as IL-7R agonists.
IL-7Rαγc binding compounds and pharmaceutical compositions comprising the IL-7Rαγc binding compounds are disclosed. IL-7Rαγc bonding compounds can act as IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.
IL-7Rα ligands and compounds comprising IL-7Rα ligands are disclosed. The IL-7Rα binding compounds include fusion proteins comprising the IL-7Rα ligands and can act as IL-7R agonists.
IL-7Rαγc binding compounds and pharmaceutical compositions comprising the IL-7Rαγc binding compounds are disclosed. IL-7Rαγc bonding compounds can act as IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.
IL-7R??c binding compounds and pharmaceutical compositions comprising the IL-7R??c binding compounds are disclosed. IL-7R??c bonding compounds can act as IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.
IL-2Rβγc binding compounds, and pharmaceutical compositions comprising the IL-2Rβγc binding compounds are disclosed. IL-2Rβγc binding compounds can act as IL-2R agonists and are useful in treating cancer, autoimmune diseases and inflammatory diseases.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Dual receptor binding compounds comprising IL-2Rß, IL-7Ra, and Ryc ligands, and pharmaceutical compositions comprising the dual receptor binding compounds are disclosed. The dual receptor binding compounds can act as IL-2R and IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.
IL-2Rβγc binding compounds, and pharmaceutical compositions comprising the IL-2Rβγc binding compounds are disclosed. IL-2Rβγc binding compounds can act as IL-2R agonists and are useful in treating cancer, autoimmune diseases and inflammatory diseases.
IL-2Rß?c binding compounds, and pharmaceutical compositions comprising the IL-2Rß?c binding compounds are disclosed. IL-2Rß?c binding compounds can act as IL-2R agonists and are useful in treating cancer, autoimmune diseases and inflammatory diseases.
yyc ligands, and pharmaceutical compositions comprising the dual receptor binding compounds are disclosed. The dual receptor binding compounds can act as IL-2R and IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.
Dual receptor binding compounds comprising IL-2Rβ, IL-7Rα, and Rγc ligands, and pharmaceutical compositions comprising the dual receptor binding compounds are disclosed. The dual receptor binding compounds can act as IL-2R and IL-7R agonists and are useful in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
Peptidyl IL-2Rα ligands and compounds comprising the IL-2Rα ligands are disclosed. The IL-2Rα ligands and compounds such as synthetic monomers, homodimers, or heteromers and recombinant fusion proteins comprising the IL-2Rα ligands can be used as targeting or imaging agents, as diagnostics or to treat cancers and autoimmune diseases.
Peptidyl IL-2Rα ligands and compounds comprising the IL-2Rα ligands are disclosed. The IL-2Rα ligands and compounds such as synthetic monomers, homodimers, or heteromers and recombinant fusion proteins comprising the IL-2Rα ligands can be used as targeting or imaging agents, as diagnostics or to treat cancers and autoimmune diseases.
IL-2Rβ ligands and IL-2Rγc ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2Rβ ligands and/or the IL-2Rγc ligands can be IL-2 receptor agonists.
IL-2Rβ ligands and IL-2Rγc ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2Rβ ligands and/or the IL-2Rγc ligands can be IL-2 receptor agonists.
IL-2R13 ligands and IL-2Ryc ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IT-2Kf3 ligands and/or the IL-2Ryc ligands can be IL-2 receptor agonists.
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
IL-2Rß ligands and IL-2Ryc ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the ??-2?ß ligands and/or the IL-2Ryc ligands can be IL-2 receptor agonists.
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
IL-2Rβ ligands and IL-2Ryc ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the ΙΤ-2Κβ ligands and/or the IL-2Ryc ligands can be IL-2 receptor agonists.
IL-2Rβ ligands and IL-2Rγc ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2Rβ ligands and/or the IL-2Rγc ligands can be IL-2 receptor agonists.
IL-2Rβ ligands and IL-2Rγc ligands and compounds comprising the ligands are disclosed. The ligands and compounds such as heterodimers and fusion proteins comprising the IL-2Rβ ligands and/or the IL-2Rγc ligands can be IL-2 receptor agonists.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Discovery, research, and development of therapeutics for the treatment and/or prevention of cytokine and/or growth factor related disorders; research and development in the pharmaceutical and biotechnology fields; research and development of pharmaceuticals and therapeutics for the treatment of cytokine and/or growth factor related disorders
